177 related articles for article (PubMed ID: 34159427)
1. Effect of Elevated pH on the Commercial Enteric-Coated Omeprazole Pellets Resistance: Patent Review and Multisource Generics Comparison.
Mohylyuk V; Yerkhova A; Katynska M; Sirko V; Patel K
AAPS PharmSciTech; 2021 Jun; 22(5):188. PubMed ID: 34159427
[TBL] [Abstract][Full Text] [Related]
2. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
Liu F; Shokrollahi H
Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
[TBL] [Abstract][Full Text] [Related]
3. Broadband Acoustic Resonance Dissolution Spectroscopy (BARDS): A rapid test for enteric coating thickness and integrity of controlled release pellet formulations.
Alfarsi A; Dillon A; McSweeney S; Krüse J; Griffin B; Devine K; Sherry P; Henken S; Fitzpatrick S; Fitzpatrick D
Int J Pharm; 2018 Jun; 544(1):31-38. PubMed ID: 29655796
[TBL] [Abstract][Full Text] [Related]
4. Design and in vitro/in vivo evaluation of multi-layer film coated pellets for omeprazole.
He W; Fan LF; Du Q; Xiang B; Li CL; Bai M; Chang YZ; Cao DY
Chem Pharm Bull (Tokyo); 2009 Feb; 57(2):122-8. PubMed ID: 19182399
[TBL] [Abstract][Full Text] [Related]
5. Use of bicarbonate buffer systems for dissolution characterization of enteric-coated proton pump inhibitor tablets.
Shibata H; Yoshida H; Izutsu K; Goda Y
J Pharm Pharmacol; 2016 Apr; 68(4):467-74. PubMed ID: 27019275
[TBL] [Abstract][Full Text] [Related]
6. Amylopectin as a subcoating material improves the acidic resistance of enteric-coated pellets containing a freely soluble drug.
Guo HX; Heinämäki J; Yliruusi J
Int J Pharm; 2002 Mar; 235(1-2):79-86. PubMed ID: 11879742
[TBL] [Abstract][Full Text] [Related]
7. [Differences in the release of omeprazole in 4 commercial preparations: influence of pH and ionic concentration].
Navarro MA; Raei N; Torres F; Granero L; García-Zaragoza E; Esplugues JV; Esteban Peris J
Gastroenterol Hepatol; 1998 Feb; 21(2):63-70. PubMed ID: 9549180
[TBL] [Abstract][Full Text] [Related]
8. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
Miner PB; Fort JG; Zhang Y
Aliment Pharmacol Ther; 2013 Jul; 38(1):62-71. PubMed ID: 23692061
[TBL] [Abstract][Full Text] [Related]
9. Solid self-nanoemulsifying drug delivery system filled in enteric coated hard gelatin capsules for enhancing solubility and stability of omeprazole hydrochloride.
Al-Nimry SS; Alkhamis KA; Altaani BM
Pharm Dev Technol; 2020 Jun; 25(5):588-600. PubMed ID: 31976799
[TBL] [Abstract][Full Text] [Related]
10. Delayed release film coating applications on oral solid dosage forms of proton pump inhibitors: case studies.
Missaghi S; Young C; Fegely K; Rajabi-Siahboomi AR
Drug Dev Ind Pharm; 2010 Feb; 36(2):180-9. PubMed ID: 20070183
[TBL] [Abstract][Full Text] [Related]
11. Development and evaluation of an omeprazole-based delayed-release liquid oral dosage form.
Ronchi F; Sereno A; Paide M; Sacré P; Guillaume G; Stéphenne V; Goole J; Amighi K
Int J Pharm; 2019 Aug; 567():118416. PubMed ID: 31175991
[TBL] [Abstract][Full Text] [Related]
12. In-vitro and in-vivo evaluation of enteric-coated starch-based pellets prepared via extrusion/spheronisation.
Dukić-Ott A; De Beer T; Remon JP; Baeyens W; Foreman P; Vervaet C
Eur J Pharm Biopharm; 2008 Sep; 70(1):302-12. PubMed ID: 18579353
[TBL] [Abstract][Full Text] [Related]
13. [Preparation of pantoprazole sodium enteric-coated pellets-type tablets].
Chen MM; Wang CR; Jin Y
Yao Xue Xue Bao; 2011 Jan; 46(1):96-101. PubMed ID: 21465814
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of a new immediate-release compound omeprazole capsule and its comparison with the enteric-coated formulation under fasting and fed conditions.
Liu Z; Ding L; Zhong S; Cao X; Jiang L; Duan H
Drug Res (Stuttg); 2013 Jul; 63(7):370-5. PubMed ID: 23558602
[TBL] [Abstract][Full Text] [Related]
15. To Flavor or Not to Flavor Extemporaneous Omeprazole Liquid.
Chuong MC; Taglieri CA; Kerr SG
Int J Pharm Compd; 2017; 21(6):500-512. PubMed ID: 29220339
[TBL] [Abstract][Full Text] [Related]
16. Relationship between drug dissolution and leaching of plasticizer for pellets coated with an aqueous Eudragit S100:L100 dispersion.
Bando H; McGinity JW
Int J Pharm; 2006 Oct; 323(1-2):11-7. PubMed ID: 16815652
[TBL] [Abstract][Full Text] [Related]
17. Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets.
Makino C; Ninomiya N; Sakai H; Orita H; Okano A; Yabuki A
Chem Pharm Bull (Tokyo); 2006 Apr; 54(4):409-14. PubMed ID: 16595936
[TBL] [Abstract][Full Text] [Related]
18. Degradation of omeprazole induced by enteric polymer solutions and aqueous dispersions: HPLC investigations.
Riedel A; Leopold CS
Drug Dev Ind Pharm; 2005 Jan; 31(2):151-60. PubMed ID: 15773282
[TBL] [Abstract][Full Text] [Related]
19. Solid-state interactions at the core-coat interface: physicochemical characterization of enteric-coated omeprazole pellets without a protective sub-coat.
Sharma VD; Akocak S; Ilies MA; Fassihi R
AAPS PharmSciTech; 2015 Aug; 16(4):934-43. PubMed ID: 25595125
[TBL] [Abstract][Full Text] [Related]
20. In vitro stability, potency, and dissolution of duloxetine enteric-coated pellets after exposure to applesauce, apple juice, and chocolate pudding.
Wells KA; Losin WG
Clin Ther; 2008 Jul; 30(7):1300-8. PubMed ID: 18691989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
